Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.78
−$0.19 · -1.46%
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Previous close
$12.78
−$0.19 · -1.46%
Regular session · ET · Market data may be delayed.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Day range
Current $12.78
52-week range
Current $12.78
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
35
Bearish
Risk
43
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Day range
Current $12.78
52-week range
Current $12.78
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 125K USD | 125K USD |
| Gross profit | — | — | — | 125K USD | 125K USD |
| Research and development | 30.5M USD | 19.31M USD | 24.51M USD | 20.79M USD | 15.18M USD |
| Selling, general, and administrative | 17.77M USD | 14.06M USD | 13.89M USD | 14.06M USD | 10.67M USD |
| Operating expenses | 48.27M USD | 33.37M USD | 38.39M USD | 34.8M USD | 25.85M USD |
| Interest income | 3.92M USD | 1.09M USD | 2.08M USD | 1.22M USD | — |
| Interest expense | 2.12M USD | 2.09M USD | 2.6M USD | 1.71M USD | — |
| Depreciation and amortization | 845K USD | 990K USD | 960K USD | 778K USD | — |
| Operating income | −48.27M USD | −33.37M USD | −38.39M USD | −34.67M USD | −25.73M USD |
| Net income | −38.18M USD | −55.18M USD | −37.94M USD | −18.79M USD | −36.12M USD |
Company facts updated Sep 7, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI27.99M0.24%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM21.08M0.03%80.51B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI19.7M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 Growth ETFIWO7.18M0.05%14.7B USD0.24%$377.54+0.12%
Vanguard Extended Market ETFVXF6.61M0.01%93.7B USD0.05%$242.66+0.14%
iShares Biotechnology ETFIBB5.64M0.05%10.73B USD0.44%$211.92-0.88%
Vanguard Russell 2000 ETFVTWO3.56M0.02%17.4B USD0.06%$119.62+0.25%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP3.41M0.13%2.67B USD0.20%$67.695+0.29%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
